Low-dose methotrexate in myeloproliferative neoplasm models.

about

Low-dose methotrexate in myeloproliferative neoplasm models.

Item

http://www.wikidata.org/entity/Q47135834

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Low-dose methotrexate in myeloproliferative neoplasm models.

@en

Low-dose methotrexate in myeloproliferative neoplasm models.

@nl

type

Item

label

Low-dose methotrexate in myeloproliferative neoplasm models.

@en

Low-dose methotrexate in myeloproliferative neoplasm models.

@nl

prefLabel

Low-dose methotrexate in myeloproliferative neoplasm models.

@en

Low-dose methotrexate in myeloproliferative neoplasm models.

@nl

P1476

Low-dose methotrexate in myeloproliferative neoplasm models.

@en

P2093

Andrew D Chantry

http://www.w3.org/2001/XMLSchema#string

Jenny Down

http://www.w3.org/2001/XMLSchema#string

John A Snowden

http://www.w3.org/2001/XMLSchema#string

Kavitha Chinnaiya

http://www.w3.org/2001/XMLSchema#string

Marie-Therese Haider

http://www.w3.org/2001/XMLSchema#string

Martin P Zeidler

http://www.w3.org/2001/XMLSchema#string

Michelle A Lawson

http://www.w3.org/2001/XMLSchema#string

P2860

Recent advances in understanding myelofibrosis and essential thrombocythemia

Methotrexate Is a JAK/STAT Pathway Inhibitor

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.

Mechanisms of Jak/STAT signaling in immunity and disease

Methotrexate: its use in the rheumatic diseases.

Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases.

P304

e336-e339

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2017.165738

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28550185

http://www.w3.org/2001/XMLSchema#string

P932

5685234

http://www.w3.org/2001/XMLSchema#string